Skip to content

Zenas BioPharma

US · ZBIO #2856 by market cap Listed 2024
23.85 -1.19 -4.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 8.95 Expensive vs history 93rd percentile
5-year average 3.76 · #449 of 514 in Biotechnology
P/E ratio -2.78 In line with history 65th percentile
5-year average -4.52 · forward -5.08
P/S ratio 172.69 Expensive vs history 83rd percentile
5-year average 264.86 · forward 43.90 · #311 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Zenas BioPharma (ZBIO) 1.62B -2.37 7.62 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value42.51 Economic moatNone UncertaintyVery High

Trading 78.3% below Morningstar's fair value estimate.

Fair value

Zenas BioPharma Inc is assigned a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 34% discount to our quantitative fair value estimate of $42.51 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 9.4, which ranks in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

Alternatively, the firm's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 11.1%, a core component of valuation, sits in the bottom 10% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Zenas BioPharma discussion 0 comments

Add a comment